Novocure Ltd (NASDAQ:NVCR) CFO Wilhelmus Cm Groenhuysen sold 25,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $80.83, for a total transaction of $2,020,750.00. Following the completion of the sale, the chief financial officer now owns 112,179 shares of the company’s stock, valued at approximately $9,067,428.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of NVCR stock traded up $3.26 during trading hours on Wednesday, hitting $78.41. The company’s stock had a trading volume of 1,119,247 shares, compared to its average volume of 741,568. The business has a fifty day moving average of $86.62 and a 200-day moving average of $61.48. The stock has a market cap of $7.38 billion, a price-to-earnings ratio of -113.64 and a beta of 2.41. Novocure Ltd has a twelve month low of $26.02 and a twelve month high of $98.70. The company has a current ratio of 5.03, a quick ratio of 4.68 and a debt-to-equity ratio of 1.01.

Novocure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.06. Novocure had a negative return on equity of 31.80% and a negative net margin of 13.84%. The firm had revenue of $86.70 million during the quarter, compared to the consensus estimate of $78.98 million. During the same period in the previous year, the firm posted ($0.17) EPS. The company’s quarterly revenue was up 41.0% compared to the same quarter last year. On average, equities analysts expect that Novocure Ltd will post -0.22 EPS for the current fiscal year.

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. lowered shares of Novocure from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $61.00 to $79.00 in a research report on Friday, July 26th. Zacks Investment Research downgraded Novocure from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st. BidaskClub lowered Novocure from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 5th. Mizuho raised their price target on Novocure from $63.00 to $91.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, ValuEngine upgraded Novocure from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 26th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Novocure presently has a consensus rating of “Buy” and an average target price of $68.00.

Large investors have recently made changes to their positions in the business. Chicago Equity Partners LLC raised its holdings in shares of Novocure by 14.5% in the second quarter. Chicago Equity Partners LLC now owns 50,925 shares of the medical equipment provider’s stock worth $3,220,000 after acquiring an additional 6,435 shares during the last quarter. Wedbush Securities Inc. acquired a new position in Novocure in the 2nd quarter valued at about $241,000. Jennison Associates LLC raised its stake in Novocure by 13.8% in the 2nd quarter. Jennison Associates LLC now owns 16,032 shares of the medical equipment provider’s stock valued at $1,014,000 after purchasing an additional 1,940 shares during the last quarter. Baillie Gifford & Co. raised its stake in Novocure by 9.8% in the 2nd quarter. Baillie Gifford & Co. now owns 8,829,449 shares of the medical equipment provider’s stock valued at $558,287,000 after purchasing an additional 789,924 shares during the last quarter. Finally, C WorldWide Group Holding A S lifted its holdings in Novocure by 92.5% in the 2nd quarter. C WorldWide Group Holding A S now owns 208,059 shares of the medical equipment provider’s stock valued at $13,156,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 66.50% of the company’s stock.

Novocure Company Profile

Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline.

Further Reading: Can systematic risk be avoided?

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.